This article is more than 5 years old. Information may no longer be current.

FDA says Sun Pharma addressed issues at facility in India

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Issues observed at Sun Pharma’s Halol facility in Gujarat, India, detailed in an FDA warning letter in December 2015, have been addressed, and the inspection is now closed, according to the company.

Sun Pharma received an FDA establishment inspection report regarding a February inspection that stated all issues have been addressed.

“This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and ... [current good manufacturing practice] compliance at all our manufacturing facilities globally,” Dilip Shanghvi, Sun Pharma managing director, said in the release.